News

PHEXCOM

Solution BY Communication

Call：+86 021-55807300

Position：Home > News >

Acadia calls early halt to Nuplazid psychosis trial after promising interim results

Acadia was stung hard after its schizophrenia hopes for flagship Nuplazid fell flat back in late July. On the heels of that failure, Acadia is calling off a trial in dementia-related psychosis (DRP)
2019/9/9
WCLC: Roche's Tecentriq comes up short in squamous lung cancer, leaving Merck's Keytruda 'unchallenged'

Roche has been hoping its Tecentriq could put up the kind of life-lengthening numbers in squamous non-small cell lung cancer (NSCLC) that could help it compete with Merck’s Keytruda—but no dice. The
2019/9/9
Pharma's worst nightmare? Leaked Democrat pricing plan calls for negotiations, price index, fines and more

Pharma watchers have been awaiting House Speaker Nancy Pelosi’s drug pricing plan, and on Monday the industry got a peek at whatDemocrats are discussing to lower drug prices. The upshot? If the House
2019/9/6
J&J scores Spravato trial win in high-risk depression. Will doctors and payers buy in?

Johnson & Johnson is attempting to change the antidepression market with its ketamine-derivative Spravato despite strict dosing requirements and a steep list price. New data in treating high-risk
2019/9/6
ICER's blasted pharma pricing for years, but now drugmakers are 'rolling up their sleeves' to cooperate

Sanofi and Regeneron's next-gencholesterol drug Praluent never lived up to early expectations, and its price tag was at least partly to blame. The cost petrified payers. Even before it—and its fellow
2019/9/5
WCLC: Merck's Keytruda dispels 'urban legend' with latest lung cancer survival win

Merck’s Keytruda-chemo combo has a history of silencing its critics when it comes to its effectiveness in previously untreated non-small cell lung cancer patients. And it may have just done it again.
2019/9/5
US FDA fast tracks Inotrem’s nangibotide for septic shock

The US Food and Drug Administration (FDA) has awarded fast track designation to French biotechnology firm Inotrem’s nangibotide programme, which is being developed to treat septic shock. Nangibotide
2019/9/4
Insilico Medicine develops new AI drug discovery system

Insilico Medicine has developed an artificial intelligence (AI)-powered system to facilitate the creation of therapeutic molecules. The AI technology GENTRL is thought to speed up the drug discovery
2019/9/4
Sandoz licences proposed multiple sclerosis biosimilar from Polpharma

Novartis unit Sandoz has signed an agreement with biopharmaceutical firm Polpharma Biologics for exclusive rights to commercialise a proposed biosimilar of Biogen’s multiple sclerosis drug natalizuma
2019/9/3
Novartis’s heart failure drug Entresto presents mixed trial results

Novartis has announced that its heart failure with reduced ejection fraction (HFrEF) drug Entresto (sacubitril/valsartan) has shown further efficacy in two Phase IV trials, PROVE-HF and EVALUATE-HF.
2019/9/3

Excipients